openPR Logo
Press release

Netherton Syndrome Clinical Trials, Pipeline Insights, Treatment Drugs, and Companies 2024

09-24-2024 04:02 AM CET | Health & Medicine

Press release from: DelveInsight Business Research LLP

Netherton Syndrome Pipeline

Netherton Syndrome Pipeline

DelveInsight's, "Netherton Syndrome- Pipeline Insight, 2024" report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Netherton Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Netherton Syndrome Research. Learn more about our innovative pipeline today! @ Netherton Syndrome Pipeline Outlook- https://www.delveinsight.com/sample-request/netherton-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Netherton Syndrome Pipeline Report
• In August 2024:- Daiichi Sankyo- A Phase 1b/2, Double-Blind, Placebo-Controlled, Randomized, Parallel-Arm Study to Explore Safety, Pharmacokinetics, and Early Clinical Signal of Efficacy of DS-2325a in Patients With Netherton Syndrome. Netherton Syndrome (NS) is a severe rare disease characterized by generalized scaling, erythema, and epidermal barrier defects. This study assessed the safety, pharmacokinetics (PK), and efficacy of DS-2325a in patients with NS.
• June 2024:- Daiichi Sankyo- A Phase 1b/2, Double-Blind, Placebo-Controlled, Randomized, Parallel-Arm Study to Explore Safety, Pharmacokinetics, and Early Clinical Signal of Efficacy of DS-2325a in Patients With Netherton Syndrome. This study will explore the safety, pharmacokinetics (PK), and early clinical signal efficacy of DS-2325a in adult patients with NS.
• June 2024:- Boehringer Ingelheim- This study is open to people with a skin disease called Netherton syndrome (NS). People can join the study if they are 12 years and older. The purpose of this study is to find out whether a medicine called spesolimab helps people with NS.
• DelveInsight's Netherton Syndrome pipeline report depicts a robust space with 5+ active players working to develop 5+ pipeline therapies for Netherton Syndrome treatment.
• The leading Netherton Syndrome Companies such as TenNor Therapeutics, KBP Biosciences, Debiopharm, Destiny Pharmaa, and others.
• Promising Netherton Syndrome Therapies such as DS-2325a, QRX003, Spesolimab, and others.

Stay informed about the cutting-edge advancements in Netherton Syndrome Treatments. Download for updates and be a part of the revolution in genetic disorder care @ Netherton Syndrome Clinical Trials Assessment- https://www.delveinsight.com/sample-request/netherton-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Netherton Syndrome Emerging Drugs Profile
• QRX003: Quoin Pharmaceuticals
QRX003 is a topical lotion, formulated with a proprietary Invisicare® delivery technology, and contains a broad- spectrum serine protease inhibitor, whose mechanism of action is intended to perform the function of a specific protein, called LEKTI. The absence of LEKTI in Netherton patients leads to excessive skin shedding resulting in a highly porous and compromised skin barrier. QRX003 is designed to lead to a more normalized skin shedding process and the formation of a stronger and more effective skin barrier.
• SXR-1096: Sixera Pharma
SXR1096 is a first-in-class, potent and selective small molecule inhibitor of kallikreins 5, 7 and 14 (KLK5, 7 and 14). The compound is formulated in a proprietary skin cream formulation designed for daily use in patients with rare skin conditions. Due to the inborn lack of the protease inhibitor LEKTI, KLK 5, 7 and 14 are overactive in the outermost layer of the skin in patients with Netherton syndrome. These drug targets can best be reached by applying the pharmaceutical directly on the skin. The disease is manifest from birth and can be life threatening in newborns.

Learn more about Netherton Syndrome Drugs opportunities in our groundbreaking Netherton Syndrome Research and development projects @ Netherton Syndrome Unmet Needs- https://www.delveinsight.com/sample-request/netherton-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Netherton Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Netherton Syndrome Products have been categorized under various Molecule types such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Discover the latest advancements in Netherton Syndrome Treatment by visiting our website. Stay informed about how we're transforming the future of genetic disorder @ Netherton Syndrome Market Drivers and Barriers, and Future Perspectives- https://www.delveinsight.com/sample-request/netherton-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Netherton Syndrome Pipeline Report
• Coverage- Global
• Netherton Syndrome Companies- TenNor Therapeutics, KBP Biosciences, Debiopharm, Destiny Pharmaa, and others.
• Netherton Syndrome Therapies- DS-2325a, QRX003, Spesolimab, and others.
• Netherton Syndrome Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Netherton Syndrome Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Netherton Syndrome Pipeline on our website @ Netherton Syndrome Drugs and Companies- https://www.delveinsight.com/sample-request/netherton-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Netherton Syndrome: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Netherton Syndrome - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Drug Name: Company Name
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II/III)
11. QRX003: Quoin Pharmaceuticals
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II)
14. SXR-1096: Sixera Pharma
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug Name: Company Name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Netherton Syndrome Key Companies
21. Netherton Syndrome Key Products
22. Netherton Syndrome- Unmet Needs
23. Netherton Syndrome- Market Drivers and Barriers
24. Netherton Syndrome- Future Perspectives and Conclusion
25. Netherton Syndrome Analyst Views
26. Netherton Syndrome Key Companies
27. Appendix

List of Top Selling Market Research Report in 2024

Brucellosis Market- https://www.delveinsight.com/report-store/brucellosis-market
Pacemakers Market- https://www.delveinsight.com/report-store/pacemakers-market
Surgical Energy Instruments Market- https://www.delveinsight.com/report-store/surgical-energy-generators-market
Intraocular Lymphoma Market- https://www.delveinsight.com/report-store/intraocular-lymphoma-market
Thrombectomy Devices Market- https://www.delveinsight.com/report-store/thrombectomy-devices-market
Ventral Hernia Market- https://www.delveinsight.com/report-store/ventral-hernia-market
Novel Drug Delivery Devices Market- https://www.delveinsight.com/report-store/novel-drug-delivery-devices
Skin Neoplasms Market- https://www.delveinsight.com/report-store/skin-neoplasms-market
Hip Replacement Devices Market- https://www.delveinsight.com/report-store/hip-reconstruction-devices-market
Varicose Vein Treatment Devices Market- https://www.delveinsight.com/report-store/varicose-vein-treatment-devices-market
Bone Growth Stimulators Market- https://www.delveinsight.com/report-store/bone-growth-stimulators-market
Sepsis Market- https://www.delveinsight.com/report-store/sepsis-market
Transcatheter Heart Valve Replacement Devices Market- https://www.delveinsight.com/report-store/transcatheter-heart-valve-replacement-devices-market
Endoscopic Ultrasound Market- https://www.delveinsight.com/report-store/endoscopic-ultrasound-market
Cardiac Monitoring Devices Market- https://www.delveinsight.com/report-store/cardiac-monitoring-devices-market
Trichomoniasis Market- https://www.delveinsight.com/report-store/trichomoniasis-market-insights
Radiodermatitis Market- https://www.delveinsight.com/report-store/radiodermatitis-market
HDAC Inhibitors Market- https://www.delveinsight.com/report-store/hdac-inhibitors-market
CXCR Inhibitors Market- https://www.delveinsight.com/report-store/c-x-c-chemokine-receptor-inhibitors-competitive-landscape-market-and-pipeline-analysis
Lactose Intolerance Market- https://www.delveinsight.com/report-store/lactose-intolerance-market
Total Knee Arthroplasty Market- https://www.delveinsight.com/report-store/total-knee-arthroplasty-market
Microscopy Device Market- https://www.delveinsight.com/report-store/microscopy-device-market
Medical Marijuana Market- https://www.delveinsight.com/report-store/medical-marijuana-market-insight
Pigment Epithelial Detachment Market- https://www.delveinsight.com/report-store/pigment-epithelial-detachment-market
Stem Cell Market- https://www.delveinsight.com/report-store/stem-cell-market
UK Healthcare Report- https://www.delveinsight.com/report-store/uk-healthcare-outlook-report

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Contact No.: +91-9650213330
City: 304 S. Jones Blvd #2432, Las Vegas

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Netherton Syndrome Clinical Trials, Pipeline Insights, Treatment Drugs, and Companies 2024 here

News-ID: 3664975 • Views:

More Releases from DelveInsight Business Research LLP

Opioid Withdrawal Syndrome Market Size in the 7MM was valued ~USD 1,302 million in 2022 and is anticipated to grow at a significant CAGR by 2034, estimates DelveInsight
Opioid Withdrawal Syndrome Market Size in the 7MM was valued ~USD 1,302 million …
DelveInsight's "Opioid Withdrawal Syndrome Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of the Opioid Withdrawal Syndrome, historical and forecasted epidemiology and the Opioid Withdrawal Syndrome market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. Download DelveInsight's comprehensive report to explore market trends, pipeline analysis, and emerging therapies @ Opioid Withdrawal Syndrome Market Size- https://www.delveinsight.com/sample-request/opioid-withdrawal-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Netherton Syndrome Treatment Market Size in the 7MM was valued at ~USD 25 million in 2024 and it is expected to grow by 2034, estimates DelveInsight
Netherton Syndrome Treatment Market Size in the 7MM was valued at ~USD 25 millio …
DelveInsight's "Netherton Syndrome Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Netherton Syndrome, historical and forecasted epidemiology as well as the Netherton Syndrome market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. Unlock key insights into the Netherton Syndrome Market! Download DelveInsight's comprehensive report to explore market trends, pipeline analysis, and emerging therapies @ Netherton Syndrome Market Size-
Nephrotic Syndrome Treatment Market Size in the 7MM reached ~USD 401 million in 2022 and it is expected to grow by 2034, estimates DelveInsight
Nephrotic Syndrome Treatment Market Size in the 7MM reached ~USD 401 million in …
DelveInsight's "Nephrotic Syndrome Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of the Nephrotic Syndrome, historical and forecasted epidemiology, and the Nephrotic Syndrome market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. Unlock key insights into the Nephrotic Syndrome Market! Download DelveInsight's comprehensive report to explore market trends, pipeline analysis, and emerging therapies @ Nephrotic Syndrome Market Size-
Leptomeningeal Metastases Market Size in 7MM was ~USD 1700 Million in 2024 and which is expected to rise in 2034, estimates DelveInsight
Leptomeningeal Metastases Market Size in 7MM was ~USD 1700 Million in 2024 and w …
DelveInsight's " Leptomeningeal Metastases Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of Leptomeningeal Metastases, historical and forecasted epidemiology, as well as the Leptomeningeal Metastases Market Trends in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. Discover Key Insights into the Leptomeningeal Metastases Market with DelveInsight's In-Depth Report @ Leptomeningeal Metastases Treatment Market Size- https://www.delveinsight.com/sample-request/leptomeningeal-metastases-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr Key Takeaways from the Leptomeningeal

All 5 Releases


More Releases for Netherton

Netherton Syndrome Market is expected to reach USD 2.5 billion by 2034
Netherton Syndrome is a rare, inherited autosomal recessive skin disorder caused by mutations in the SPINK5 gene, which encodes the serine protease inhibitor LEKTI. The condition is characterized by ichthyosiform erythroderma, hair shaft abnormalities (trichorrhexis invaginata), and immune system dysfunction, often leading to recurrent infections and severe allergic manifestations. The prevalence is estimated at 1 in 200,000 births worldwide, making it a challenging orphan disease to diagnose and treat. Download Full
Evolving Market Trends In The Netherton Syndrome Industry: Advancements In Serin …
Stay ahead with our updated market reports featuring the latest on tariffs, trade flows, and supply chain transformations. What Is the Expected Netherton Syndrome Market Size During the Forecast Period? The market size of the Netherton syndrome has experienced significant growth over the recent years. It is projected to escalate from $1.15 billion in 2024 to $1.27 billion in 2025, reflecting a compound annual growth rate (CAGR) of 10.2%. The notable growth
Netherton Syndrome Pipeline, Therapeutics Assessment, Clinical Trials, Drugs, an …
DelveInsight's, "Netherton Syndrome Pipeline Insight 2024" report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Netherton Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore our latest breakthroughs in Netherton Syndrome Research. Learn more about
Netherton Syndrome Pipeline Drugs, FDA Approvals, and Companies 2024
DelveInsight's, "Netherton Syndrome- Pipeline Insight, 2024" report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Netherton Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore our latest breakthroughs in Netherton Syndrome Research. Learn more about
Netherton Syndrome Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MO …
DelveInsight's, "Netherton Syndrome- Pipeline Insight, 2024" report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Netherton Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore our latest breakthroughs in Netherton Syndrome Research. Learn more about
Netherton Syndrome Market Size, Share, Trends, Insights, Growth 2032
Introduction A. Overview of Netherton Syndrome Netherton syndrome is a rare genetic disorder that primarily affects the skin, hair, and immune system. This condition is characterized by ichthyosis linearis circumflexa (red, scaly skin), trichorrhexis invaginata (bamboo hair), and a predisposition to atopic conditions such as eczema, asthma, and allergies. The syndrome is caused by mutations in the SPINK5 gene, which encodes the LEKTI protein, crucial for skin barrier function. Due to